– First preclinical data presented for structurally diverse oral Factor XIIa inhibitors - – Additional Sebetralstat data also presented - CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Jun. 8, 2022-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company...

CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Jun. 3, 2022-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted one newly-hired employee inducement options to purchase an aggregate of 20,000 shares of...

CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Jun. 1, 2022-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced it will be...

– Patrick A. Treanor Appointed Effective Immediately – – Dan Soland Resigns in Planned Transition – CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--May 27, 2022-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development,...

– “Sebetralstat” Approved by WHO and USAN – CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--May 17, 2022-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease...

CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Apr. 11, 2022-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced it will be...

CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Apr. 4, 2022-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted one newly-hired employee inducement options to purchase an aggregate of 7,000 shares of...

CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Mar. 22, 2022-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the publication...

– KVD900 Phase 3 KONFIDENT Trial Initiated – – KVD824 Phase 2 KOMPLETE Clinical Trial Enrollment on Track – CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Mar. 10, 2022-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery,...

-KONFIDENT to Evaluate KVD900 As First Oral On-Demand Therapy for HAE- -KONFIDENT Designed to Support Broad Label for Treatment of All HAE Attacks- CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Mar. 7, 2022-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical...